Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

Active, not recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

May 7, 2025

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2025

Conditions

Metastatic HER2+ Advanced Breast Cancer

Interventions

DRUG

Tucatinib

As provided in real world practice.

DRUG

Trastuzumab

As provided in real world practice.

DRUG

Capecitabine

As provided in real world practice.

Trial Locations (1)

Pfizer, New York